The CDA-AMC recommended that Ebglyss not be reimbursed by public drug plans, excluding Quebec, for the treatment of ...

Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

Shares of Aclaris Therapeutics ACRS rallied 53.2% on Monday and gained another 8.9% during the after-market hours following ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

As Delhi’s AQI hits a new high, it is essential to know the effect it can have on our skin. Know the preventive measures from ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their resubmitted supplemental biologics license ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- ...

In a completed Phase 2a, single-arm, proof-of-concept trial in the United States in 22 patients with moderate to severe atopic dermatitis, BSI-045B was observed to have a pharmacodynamic, safety and ...

The licensing deal with Biosion involves an experimental treatment for severe asthma and skin disorder known as atopic ...

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...